⁶⁸Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors – a head-to-head comparison with DOTATOC and FDG PET/CT (#15)

4:00 PM

Michael Lassmann

Optimising Peptide Receptor Radionuclide Therapy (PRRT) - (submitted abstracts)

Patient dosimetry assessment with the somatostatin receptor antagonist ⁶⁸Ga-labelled OPS202 in the first clinical study of gastroenteropancreatic neuroendocrine tumors (GEP-NET) (#67)

8:30 AM

Uta Eberlein

Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours

In-vitro dose calibration of the DNA damage assay for internal irradiation of blood lymphocytes with the PET nuclide ⁶⁸Ga (#106)

8:30 AM

Uta Eberlein

Conference Breakfast: Moderated Poster Walk - Novel Theranostics

DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy (PRRT) patients with personalised high activities (#7)

11:45 AM

Uta Eberlein

Refining and Defining NET Targets (submitted abstracts)

Phase I/II open-label trial to evaluate the safety and preliminary efficacy of ¹⁷⁷Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors (#57)

8:30 AM

Rod Hicks

Conference Breakfast: Moderated Poster Walk - Neuroendocrine tumours

Dosimetry in 177Lu treatment: what we know and what we do not know (#18)

5:10 PM

Michael Lassmann

From Preclinical Research to Individualised Patient Dosimetry